News | April 09, 2007

Bayer HealthCare Pharmaceuticals Officially Launched in U.S.

April 10, 2007 - Bayer HealthCare Pharmaceuticals Inc. announced its official U.S. launch. The new company incorporates the former Berlex Inc. into Bayer HealthCare Pharmaceuticals, as part of Bayer's acquisition of Schering AG, Germany, Berlex's former parent company.

Bayer HealthCare Pharmaceuticals Inc., headquartered in Wayne, NJ, is the U.S.-based pharmaceuticals unit of Bayer HealthCare. Bayer HealthCare's pharmaceutical business is dedicated to developing, manufacturing and marketing products that help improve human health, and globally ranks among the top 10 specialty pharmaceutical companies. The global pharmaceutical business employs more than 40,000 people, with approximately 5,500 employees in the U.S.

The company's global Oncology and Specialized Therapeutics business units, as well as certain U.S.-based global drug development groups and other business support functions, will be housed in its Montville, N.J. offices. The establishment of Bayer HealthCare Pharmaceuticals is expected to bring an estimated 300 new jobs to New Jersey.

The combined company has a robust research and development program with a strong product pipeline geared toward developing meaningful new therapeutic options to fulfill unmet medical needs. As a result of these two companies combining forces, research and development activities have been consolidated into three major sites (Berkeley, Calif., Berlin and Wuppertal, Germany). The Berkeley facility is an important R&D center for protein-based biologics and will house the company's global Hematology/Cardiology business.

Research in Diagnostic Imaging, Women's Healthcare and Oncology will be based in Berlin. Wuppertal will house the core of the company's Cardiology research. Both locations have significant capabilities and activities in target discovery, lead generation and optimization, drug metabolism and pharmacokinetics, toxicology and clinical pharmacology.

Bayer also will continue operations in Washington State to manufacture the company's white blood cell growth factor.

For more information, contact www.berlex.com.

Related Content

Elekta Introduces Strategy for Precision Radiation Medicine at ASTRO 2018

Elekta SmartClinic is one of the key features in the Mosaiq Plaza suite of data-focused integrative oncology software

News | Radiation Therapy | October 30, 2018
At the American Society for Radiation Oncology (ASTRO) Annual Meeting, Oct. 21-24 in San Antonio, Elekta introduced the...
ViewRay and Miami Cancer Institute Host Symposium on MR-Guided Radiation Therapy
News | Image Guided Radiation Therapy (IGRT) | October 05, 2018
October 5, 2018 — Leading oncology experts from around the world recently met to discuss the integration of...
Turkish Hospital Begins MR-Guided Radiation Therapy With Viewray MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | September 21, 2018
ViewRay Inc. announced that Acibadem Maslak Hospital in Istanbul, Turkey has begun treating patients with ViewRay's...
Elekta Unity High-Field MR-Linac Receives CE Mark
News | Image Guided Radiation Therapy (IGRT) | June 18, 2018
Elekta announced that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has received CE mark,...
Washington University in St. Louis Begins Clinical Treatments With ViewRay MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | June 14, 2018
June 14, 2018 — The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in S
ViewRay Unveils New Soft Tissue Visualization Technologies for MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | April 30, 2018
ViewRay Inc. announced new magnetic resonance imaging (MRI) technologies under development for its MRIdian Linac...
​ITN Celebrates World Cancer Day 2018
News | Radiation Oncology | February 01, 2018
World Cancer Day takes place annually on Feb.